Total Funding
60
74
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
23 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
40724
Incanthera develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific
Laurence Patterson: Founding Shareholder
Simon Ward: CEO
About the Company
Incanthera Ltd. develops cancer treatment drugs. Its ICT-2588 is a lead compound that is activated within solid tumours by a specific matrix metalloprotease enzyme. The company was incorporated in 2010 and is based in Liverpool, United Kingdom.
